Professor in the Department of Microbiology and Immunology and Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore He is holding a Joint Senior Principal Investigator in the Institute of Molecular and Cell Biology (IMCB), A*STAR. He is the Director of the Biosafety Level 3 Facility NUS. Justin is actively engaged in the study of the molecular virology of positive-sense RNA viruses of medical importance including SARS CoV-2, human enteroviruses that cause HFMD as well as mosquito-borne viruses including Dengue, Zika, West Nile and Chikungunya. The outcomes from these studies are helping to pave the roadmap towards the successful development antiviral strategies including next generation vaccines and antiviral therapeutics. Fifteen patents and numerous scientific awards have been received from his current research. Justin has published over 160 international peer-reviewed scientific publications, six book chapters and over 200 conference papers. A number of these scientific papers are published in top-notch journals including Cell, Science, Nature Immunology, Science Translational Medicine, Nature Communications, PNAS, EBiomedicine, PLoS Pathogens. A/P Chu is among the World’s Top 2% Scientists ranking published by Stanford University based on single-year data on citations received during the calendar year 2021, 2022 and 2023. He was the elected President of the Asia-Pacific Society of Medical Virology (2019-2024) and currently the elected President of the Singapore Society for Microbiology and Biotechnology.